ethyl 5-methyl-6-(2-naphthylsulfanyl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indole-2-carboxylate | 868161-15-3

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: ethyl 5-methyl-6-(2-naphthylsulfanyl)-1,3,4,5-tetrahydro-2H-pyrido[4,3-b]indole-2-carboxylate
• 英文别名: ethyl 5-methyl-6-naphthalen-2-ylsulfanyl-3,4-dihydro-1H-pyrido[4,3-b]indole-2-carboxylate
• CAS: 868161-15-3
• 化学式: C₂₅H₂₄N₂O₂S
• 分子量: 416.544
• InChiKey: LZSQVYNBSQXTKL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  30
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  59.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists
  申请人：Lee Taekyu

  公开号：US20050239768A1

  公开（公告）日：2005-10-27

  The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R 1 , R 4a , R 5 , R 6 , R 7 , R 8 , R 9 , m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).

  本申请提供了根据式（I）的新化合物，包括所有立体异构体、溶剂化合物、前药酯以及其药学上可接受的盐形式，其中R1、R4a、R5、R6、R7、R8、R9、m和X在此处描述。此外，本申请提供了包括至少一种符合式（I）的化合物的新型药物组合物。此外，本申请提供了治疗有需要的患者的方法，包括给予至少一种符合式（I）的化合物的治疗有效剂量。
• US7592454B2
  申请人：——

  公开号：US7592454B2

  公开（公告）日：2009-09-22
• [EN] SUBSTITUTED HEXAHYDRO-PYRIDOINDOLE DERIVATIVES AS SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS<br/>[FR] DÉRIVÉS DE SUBSTITUTS HEXAHYDRO-PYRIDOINDOLE COMME AGONISTES DE RÉCEPTEUR DE LA SÉROTONINE ET ANTAGONISTE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2005105082A1

  公开（公告）日：2005-11-10

  The present application provides novel compounds according to Formula (I): including all stereoisomers, solvates, prodrug esters and pharmaceutically acceptable salt forms thereof, wherein R1, R4a, R5, R6, R7, R8, R9, m, and X are described herein. Additionally, the present application provides novel pharmaceutical compositions comprising at least one compound according to Formula (I). Further, the present application provides methods of treating a patient in need comprising administering a therapeutically effective amount of at least one compound according to Formula (I).